Maublant J C, Citron B, Lipiecki J, Mestas D, Bailly P, Veyre A, de Riberolles C, Ponsonnaille J
Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.
Am Heart J. 1995 Feb;129(2):306-14. doi: 10.1016/0002-8703(95)90013-6.
The myocardial uptake of rest-injected technetium 99m sestamibi on single-photon-emission computed tomographic images was assessed in 25 patients. All had an area of myocardial dysfunction that could be related to a coronary artery stenosis. None of the patients had clinical evidence of a myocardial infarction. Three months after revascularization, viability was demonstrated by contrast angiography and center-line analysis in 21 (78%) of the 27 formerly hibernating territories. Among these, none had a transmural defect, and 38% had a normal technetium 99m-sestamibi uptake. The four transmural preoperative defects were located in territories without viability. Eight of the 9 territories that were normal at scintigraphy proved to be viable postoperatively. It is concluded that as long as some residual technetium 99m-sestamibi uptake is present, viable myocardium is also present.
对25例患者单光子发射计算机断层扫描图像上静息注射的锝99m-司他比的心肌摄取情况进行了评估。所有患者均有与冠状动脉狭窄相关的心肌功能障碍区域。所有患者均无心肌梗死的临床证据。血运重建三个月后，27个先前冬眠心肌节段中的21个（78%）通过造影剂血管造影和中心线分析显示有存活心肌。其中，无一例有透壁缺损，38%的患者锝99m-司他比摄取正常。术前四个透壁缺损位于无存活心肌的节段。闪烁扫描正常的9个节段中有8个术后证明有存活心肌。结论是，只要存在一些残余的锝99m-司他比摄取，就存在存活心肌。
